| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/20/1999 | CN1205738A OB protein derivatives having prolonged half-life |
| 01/20/1999 | CN1205707A Sugar-substituted 2-azetidinones useful as hypocholesterolemic gents |
| 01/20/1999 | CN1205703A Polymorphic foams of growth hormone secretagogue |
| 01/20/1999 | CN1205695A N-substituted dioxothiazolidylbenzamide derivatives and process for producing same |
| 01/20/1999 | CN1205689A Novel 2,3,5-trimethyl-4-hydroxy anilide derivatives, prepn. thereof and therapeutical use thereof |
| 01/20/1999 | CN1205205A Pyrazolopyridine compound and processes for preparation thereof |
| 01/19/1999 | US5861496 Nucleic acid and amino acid sequences of a novel squalene epoxidase and to the use of these sequences in the diagnosis, prevention, and treatment of diseases such as hypercholesterolemia and atherosclerosis. |
| 01/19/1999 | US5861401 Treatment of congestive heart failure |
| 01/19/1999 | US5861394 Use of N-substituted phenothiazines |
| 01/19/1999 | US5861379 Chimeric fatty body-pro-GRF analogs with increased biological potency |
| 01/19/1999 | US5861309 Amino acid sequences encoding it, vectors for its expression in yeast, bacterial, and mammalian cells; research into the characterization of the pharmacology of individual human alpha 1 receptor subtypes |
| 01/19/1999 | US5861048 Dissolving aa alkaline earth metal or iron with a phosphorylated saccharide or one bound to a protein or peptide for use in feeds, fertilizers, foods beverages or tablets |
| 01/15/1999 | CA2220849A1 A human pelota homolog |
| 01/14/1999 | WO1999001466A1 Secreted proteins and polynucleotides encoding them |
| 01/14/1999 | WO1999001452A1 Novel cycloalkyl substituted imidazoles |
| 01/14/1999 | WO1999001439A1 Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| 01/14/1999 | WO1999001430A1 Method for preparing a substituted perhydroisoindole |
| 01/14/1999 | WO1999001426A1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| 01/14/1999 | WO1999001421A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| 01/14/1999 | WO1999001164A1 Cloning pigs using donor nuclei from differentiated cells |
| 01/14/1999 | WO1999001151A1 Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity |
| 01/14/1999 | WO1999001149A1 Health supplement |
| 01/14/1999 | WO1999001136A1 Novel substituted imidazole compounds |
| 01/14/1999 | WO1999001135A1 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
| 01/14/1999 | WO1999001131A1 Novel substituted imidazole compounds |
| 01/14/1999 | WO1999001130A1 Novel substituted imidazole compounds |
| 01/14/1999 | WO1999001128A1 Certain diarylimidazole derivatives; a new class of npy specific ligands |
| 01/14/1999 | WO1999001126A1 Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
| 01/14/1999 | WO1999001122A1 Delayed-release dosage forms of sertraline |
| 01/14/1999 | WO1999001121A1 Sertraline salts and sustained-release dosage forms of sertraline |
| 01/14/1999 | WO1999001113A1 Gelatine encapsulated solution dosage forms of sertraline |
| 01/14/1999 | WO1999001110A1 Targeted liposomal constructs for diagnostic and therapeutic uses |
| 01/14/1999 | WO1999001044A1 Palatable elemental medical food |
| 01/14/1999 | CA2297791A1 Health supplement |
| 01/14/1999 | CA2296014A1 Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| 01/14/1999 | CA2295762A1 Novel cycloalkyl substituted imidazoles |
| 01/14/1999 | CA2295748A1 Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
| 01/14/1999 | CA2295294A1 Cloning pigs using donor nuclei from differentiated cells |
| 01/14/1999 | CA2295228A1 Novel substituted imidazole compounds |
| 01/14/1999 | CA2295212A1 Secreted proteins and polynucleotides encoding them |
| 01/14/1999 | CA2294900A1 Targeted liposomal constructs for diagnostic and therapeutic uses |
| 01/14/1999 | CA2294898A1 Certain diarylimidazole derivatives; a new class of npy specific ligands |
| 01/14/1999 | CA2294824A1 Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity |
| 01/14/1999 | CA2294524A1 Novel substituted imidazole compounds |
| 01/14/1999 | CA2294522A1 Novel substituted imidazole compounds |
| 01/14/1999 | CA2290509A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| 01/14/1999 | CA2236489A1 Novel compounds |
| 01/13/1999 | EP0889906A1 Amphipathic molecules as cholesterol and other lipid uptake inhibitors |
| 01/13/1999 | EP0889893A1 Azaspiroderivatives |
| 01/13/1999 | EP0889892A1 Azaspiro derivatives |
| 01/13/1999 | EP0889876A1 Meta-substituted phenylene sulphonamide derivatives |
| 01/13/1999 | EP0889875A1 Cyclopropyl alkanoic acid derivatives |
| 01/13/1999 | EP0889737A1 Obesity protein compounds and formulations thereof |
| 01/13/1999 | EP0889726A1 Novel cycloalkyl substituted imidazoles |
| 01/13/1999 | EP0847278A4 Analogs of parathyroid hormone |
| 01/13/1999 | EP0671910A4 Glaucoma treatment. |
| 01/13/1999 | EP0627438B1 Methanediphosphonate derivative, process for producing the same, and pharmaceutical use thereof |
| 01/13/1999 | EP0555327B1 Alkylidene analogs of 1'-aminospiro-[isoquinoline- 4(1h),3'-pyrrolidine]-1,2',3,5'(2h)-tetrones useful as aldose reductase inhibitors in vivo |
| 01/13/1999 | CN1205009A Pyrazolopyrimidines type compound |
| 01/13/1999 | CN1204965A Anion exchange resin-containing tablets |
| 01/12/1999 | US5859257 Isoxazole compounds as cyclooxygenase inhibitors |
| 01/12/1999 | US5859240 Reduction of imine group; oxidation; salt formation |
| 01/12/1999 | US5859062 Guanylhydrazones and their use to treat inflammatory conditions |
| 01/12/1999 | US5859044 Treating diabetes, hyperglycemia, obesity; increasing content of lean meat in animals |
| 01/12/1999 | US5859037 Sulfonylurea-glitazone combinations for diabetes |
| 01/12/1999 | US5859007 Treatment of diabetes, obesity |
| 01/12/1999 | US5859004 Use of heterocyclic compounds for the treatment of conditions caused by malfunctioning of the nicotinic cholinergic system |
| 01/12/1999 | US5858995 Administering to humans and animals in the treatment of diseases caused by abnormal bone metabolism |
| 01/12/1999 | US5858968 Autoimmune model: insulin not used for its endocrinologic effect (does not affect blood sugar levels), but to damp down the host's autoimmune response and prevent autoimmune destruction of pancreatic beta cells, allowing oral dosing |
| 01/12/1999 | US5858716 H2CAA71 polynucleotides |
| 01/12/1999 | US5858701 DNA encoding an insulin receptor substrate |
| 01/12/1999 | US5858684 Contacting recombinant cell with test compound which is not verapamil or gallopamil, determining ability of compound to affect activities of inorganic ion receptor; determination of agonist and antagonist drugs |
| 01/12/1999 | US5858444 Blending fully hydrogenated oil consisting only of stearic acid and/or palmitic acid residues with another oil; low calorie foods and beverages |
| 01/12/1999 | US5858376 Introducing into cell isolated protein derived from herpes simplex virus |
| 01/12/1999 | CA2070503C A-c-b proinsulin, method of manufacturing and using same, and intermediates in insulin production |
| 01/07/1999 | WO1999000420A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 01/07/1999 | WO1999000373A1 Benzimidazole derivatives |
| 01/07/1999 | WO1999000353A1 Novel thyroid receptor ligands and method |
| 01/07/1999 | WO1999000146A1 Development and use of human pancreatic cell lines |
| 01/07/1999 | WO1999000123A1 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
| 01/07/1999 | WO1999000122A1 Method for reducing body weight |
| 01/07/1999 | WO1999000116A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 01/07/1999 | WO1998045427A3 Insulin-like growth factor agonist peptides |
| 01/07/1999 | WO1998040049A3 Specific magnetosome, method for the production and use thereof |
| 01/07/1999 | EP0889126A2 YNL075W/HTXFT19 polypeptide |
| 01/07/1999 | EP0888773A1 Use of petroselinic acid for the treatment of inflammations of superficial tissues |
| 01/07/1999 | EP0888350A1 Azolobenzazepine derivatives as neurologically active agents |
| 01/07/1999 | EP0888344A1 Spirocycle integrin inhibitors |
| 01/07/1999 | EP0888337A1 Piperidone tachykinin antagonists |
| 01/07/1999 | EP0888335A1 Novel pyrimidine compounds useful in treating cytokine mediated diseases |
| 01/07/1999 | EP0888333A1 Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 01/07/1999 | EP0888317A1 Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma |
| 01/07/1999 | EP0888278A1 Antidiabetic agents |
| 01/07/1999 | EP0888121A1 Use of vasopressin receptor antagonist for regulation of acth release |
| 01/07/1999 | EP0888112A1 New use of ammonium compounds and/or urea |
| 01/07/1999 | CA2295925A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 01/07/1999 | CA2295747A1 Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
| 01/07/1999 | CA2294505A1 Benzimidazole derivatives |
| 01/07/1999 | CA2294232A1 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 01/06/1999 | CN1203916A Tetrahydroimidazo [2,1-a] isoquinoline derivatives |